Nautilus Biotechnology

What Nautilus Biotechnology does

Nautilus Biotechnology is a publicly traded life sciences company (NASDAQ: NAUT) founded in 2016, headquartered in San Carlos, California, with a research headquarters in Seattle. The company is developing a single-molecule proteomics platform—centered on its proprietary Iterative Mapping technology and commercialized as the Voyager Platform—that is designed to analyze up to 10 billion intact proteins and proteoforms in a single run, targeting measurement of 95% of the human proteome. The technology uses hyper-dense nanoarrays, multi-affinity probes binding short peptide sequences, and machine learning algorithms to convert probe binding patterns into quantified protein identifications, with data delivered through a cloud-based analysis portal as simple CSV files with standard visualization tools.

The company is pre-commercial, with a planned commercial launch of the Voyager Platform in late 2026. The business model combines direct enterprise field sales to pharmaceutical, biotechnology, and academic research customers with a consumables-driven recurring revenue model; pricing signals indicate an instrument package of approximately $1 million and recurring consumables of approximately $500,000 per customer annually. Nautilus is currently generating early validation revenue through the Iterative Mapping Early Access Program, anchored by first customer Baylor College of Medicine (NIH U01-funded cancer proteomics study) and field evaluation partner Buck Institute for Research on Aging, with additional collaborations in Alzheimer's (Tau Proteoforms Assay) and Parkinson's (alpha-synuclein work with Weill Cornell Medicine-Qatar and the Michael J. Fox Foundation). As of Q1 2026, the company reported $143.4 million in cash and investments, operating expenses of $16.1 million (down 14% year-over-year), a net loss of $14.7 million, and management-stated cash runway extending through 2027.

Name

Nautilus Biotechnology

Legal name

Nautilus Biotechnology, Inc.

Website

https://nautilus.bio

Company type

Public

Founded year

2016

Operating status

Operating

Headcount range

101–250 employees

Short description

Nautilus Biotechnology is a pre-commercial life sciences company building the Voyager Platform, a single-molecule proteomics instrument using proprietary Iterative Mapping technology to quantify proteins and proteoforms for pharmaceutical, biotechnology, and academic research customers, with commercial launch planned for late 2026.

Ownership category

akta.pro rank

Product category

Proteomics Instruments

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516), Scientific Research and Development Services (5417)

SIC

Laboratory Analytical Instruments (3826), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Single-Cell & Spatial Omics Discovery Platforms (target ID/validation, functional profiling) (HLAAAIAF)

akta.pro secondary industries

Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation) (HLAAAIAI), AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO), Bioinformatics & Multi-omics Analysis Software (HLAGAJAD), Library & Diversity Generation Platforms (display libraries, DNA-encoded libraries for biologics, variant libraries) (HLAAAIAL)

Keywords

• Single-molecule proteomics
• Protein analysis platform
• Proteome quantification
• Biomarker discovery technology
• Drug development proteomics

Headquarters

HQ city

San Carlos

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Voyager Platform Instrument Sales: Sale of the Voyager proteomics instrument with estimated initial instrument package priced at approximately $1 million. Hardware sales represent the upfront capital investment for customers.
2. Consumables Revenue: Recurring consumables revenue from proprietary reagents and flow cells. Projected at approximately $500,000 annual consumables per customer. This creates recurring revenue stream from the installed base.
3. Early Access Program: Early Access Program provides initial revenue and customer validation ahead of broader commercial launch in late 2026. First customer Baylor College of Medicine participating through NIH-funded study.

Pricing tiers

Go-to-market motion2 records

Distribution channels3 records

Marketing channels12 records

Core offering

Nautilus Biotechnology develops the Voyager Platform, a proteomics instrument that uses proprietary Iterative Mapping technology to analyze up to 10 billion single protein molecules and proteoforms simultaneously in a single run. The platform integrates reagents, fluidics, imaging, ultra-dense nano-array flow cells, and cloud-based data analysis to deliver comprehensive proteome coverage with up to 9 orders of magnitude dynamic range. The company targets pharmaceutical and biotechnology companies, academic research institutions, and clinical researchers for drug target discovery, biomarker identification, and mechanism of action studies.

Product overview

Nautilus Biotechnology offers the Voyager Platform as its core proteomics instrument product, which integrates reagents, fluidics, imaging, and ultra-dense nano-array flow cells to enable the company's proprietary Iterative Mapping technology. Iterative Mapping is a single-molecule analysis method that quantifies proteins and proteoforms across the proteome using multi-affinity probes and machine learning algorithms. The product portfolio includes specific assays such as the Tau Proteoforms Assay (available through the Early Access Program) and the Alpha-Synuclein Assay (in development for Parkinson's research). Users access the platform through the Iterative Mapping Early Access Program and analyze results via the Cloud Data Analysis Portal, with commercial launch planned for late 2026.

Differentiator

Problem solved

Functional benefit

Brands

• Voyager Platform: The Nautilus Voyager Platform consists of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells enabling Iterative Mapping and cloud-based analysis of single-molecule data outputs.
• Iterative Mapping

Products and services

• Voyager Platform The Nautilus Voyager Platform is a proteomics instrument consisting of integrated reagents, fluidics, imaging, and ultra-dense nano-array flow cells that enable Iterative Mapping and cloud-based analysis of single-molecule data outputs. It is designed to analyze up to 10 billion single protein molecules across three Voyager Flow Cells in a single run.
• Tau Proteoforms Assay A validated assay targeting tau proteoforms for Alzheimer's and neurodegenerative disease research, offered as the first assay in the Iterative Mapping Early Access Program. Researchers at the Buck Institute mapped up to 768 distinct tau proteoforms across different brain regions using this assay.
• Alpha-Synuclein Assay An assay in development for studying alpha-synuclein protein linked to Parkinson's disease, being developed in collaboration with Weill Cornell Medicine-Qatar and supported by a $1.6 million grant from The Michael J. Fox Foundation.
• Iterative Mapping Early Access Program A program offering scientists initial access to the Nautilus single-molecule proteomic analysis method ahead of broader commercial availability, with participants receiving support for data interpretation and comprehensive proteome coverage.

Quantifiable outcome

• Platform can analyze up to 10 billion intact proteins and proteoforms in a single run
• +3 more outcomes

Named customers2 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature6 records

Partnerships

Three partnerships are on record, tiered flagship and core.

• Baylor College of MedicineflagshipStrategic or Co-development Partner · 18 March 2026First customer of Iterative Mapping Early Access Program for Voyager platform. Partnership involves an NIH U01-funded study where Baylor researchers will use Nautilus' single-molecule proteomics technology to develop a computational toolkit for identifying aberrant protein isoforms in cancer research. Project led by Professors Bing Zhang and Yongchao Dou aims to enable direct comparison of transcriptional and proteomic changes.
• Weill Cornell Medicine-QatarcoreStrategic or Co-development Partner · 29 January 2026$1.6 million research collaboration to study alpha-synuclein protein connection to Parkinson's disease. Project will leverage Nautilus' single-molecule proteomics platform and WCM-Q's expertise in chemical biology and neurology to develop assay capable of measuring specific proteoforms for early detection and disease monitoring.
• Buck Institute for Research on AgingcoreStrategic or Co-development Partner · 3 November 2025Field evaluation site where first external field evaluation unit was installed and tested, generating highly reproducible data in neurodegenerative disease samples. Collaboration focuses on the role of tau proteoforms in neurodegeneration. Platform successfully mapped up to 768 distinct tau proteoforms across different brain regions.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Olink Proteomics: Swedish-based proteomics company offering the Olink platform for high-throughput protein biomarker discovery using proximity extension assay technology. Directly comparable as a proteomics platform serving pharma/biotech with protein quantification solutions, though using a different affinity-based approach than Nautilus.
• SomaLogic: Proteomics company operating the SomaScan platform that measures 7,000+ proteins using SOMAmer aptamer reagents. Closest direct competitor to Nautilus in terms of target market (pharma/biotech/academic) and proteomics platform offering, and several Nautilus senior hires come from SomaLogic.
• Seer: NASDAQ-listed proteomics company (SEER) developing the Proteograph product suite for deep, unbiased proteomic analysis using engineered nanoparticle technology. Direct competitor targeting the same single-molecule/sensitive proteomics segment and investor base as Nautilus.
• 10x Genomics: Single-cell and spatial biology platform company whose technology parallels Nautilus's single-molecule analysis approach. Comparable in serving omics researchers with novel single-cell-level tools and shares multiple scientific advisory relationships (Parag Mallick, etc.) in the broader omics community.
• Standard BioTools: Life sciences tools company (formerly Fluidigm) providing mass cytometry and imaging instruments. Comparable as a smaller-cap public life science instruments company with similar customer base (academic, pharma research) facing the challenge of scaling consumables revenue.

Emerging players

• Quanterix: Single-molecule detection company offering Simoa platform for ultra-sensitive protein detection. Comparable in pursuing single-molecule protein measurement, though focused on immunoassay-based detection versus Nautilus's nanoarray/affinity probe architecture.
• NanoString Technologies: Spatial biology and multiplexed omics platform company whose GeoMx and CosMx instruments address similar multi-omic research applications. Comparable in pioneering a novel spatial/multi-omic platform competing for the same research budget, and a prior employer of Nautilus's VP of Marketing.

Broad incumbents

• Thermo Fisher Scientific: Mass spectrometry and analytical instruments leader whose Orbitrap mass spec platforms dominate current proteomics. The primary incumbent whose installed-base workflows Nautilus must displace or complement with its single-molecule alternative.
• Bio-Techne: Large life sciences tools and reagents company with protein analysis product lines including Simple Western and proteomics reagents. Comparable as a public proteomics-adjacent reagent/tools company with established consumables model.
• Bruker Corporation: Mass spectrometry and proteomics instruments company whose timsTOF and other MS platforms compete head-to-head with Nautilus's target value proposition in proteomics workflows. Major incumbent in life sciences analytical instruments.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/playlist?list=PLkCoAEG71HZUoA4MhWjWk1JSsn9VbKmW_
• LinkedInlinkedin.com/company/nautilus-biotechnology

Revenue estimate

Valuation estimate

Number of profiles

Profiles20 records

Funding overview

Funding rounds4 records

Investors16 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Nautilus Biotechnology